Dapagliflozin and sacubitril on myocardial microperfusion in patients with post-acute myocardial infarction heart failure and type 2 diabetes

Table 4 Comparison of indexes related to cardiac function between the two groups

Item	Control group (n = 47)		t	P value	Observation group (n = 51)		t	P value
	Before treatment	After treatment			Before treatment	After treatment
LVEF (%)	43.26 ± 5.21	50.25 ± 5.78a	-5.60	< 0.01	42.97 ± 5.74	55.69 ± 6.01a,c	-10.86	< 0.01
LVESD (mm)	44.21 ± 3.89	38.95 ± 3.41a	9.38	< 0.01	44.11 ± 4.03	34.41 ± 3.26a,c	15.70	< 0.01
LVEDD (mm)	59.78 ± 4.41	54.63 ± 4.05a	7.24	< 0.01	60.23 ± 4.52	51.78 ± 3.69a,c	9.17	< 0.01
LVMI (g/m2)	115.02 ± 16.45	102.89 ± 13.04a	4.68	< 0.01	113.87 ± 17.14	95.36 ± 10.47a,c	7.51	< 0.01
LVRI (g/mL)	1.61 ± 0.15	1.46 ± 0.12a	4.92	< 0.01	1.59 ± 0.18	1.37 ± 0.11a,c	7.21	< 0.01

^aP < 0.05 vs before treatment.

^cP < 0.05 vs control group.

LVEF: Left ventricular ejection fraction; LVESD: Left ventricular end-systolic diameter; LVEDD: Left ventricular end-diastolic diameter; LVMI: Left ventricular mass index; LVRI: Left ventricular remodeling index.